Rallybio Corporation Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for RLYB, updated each market day.
RLYB AI Sentiment
AI predicts Rallybio Corporation Common Stock stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Rallybio Corporation Common Stock
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
Sector
Exchange
Market Cap
$43,428,231
Cap Tier
Employees
14
Headquarters
NEW HAVEN, CT
Listed Since
July 29, 2021
Website
RLYB Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
RLYB Volatility
Rallybio Corporation Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
